Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan.

Chuang WL, Dai CY, Chen SC, Lee LP, Lin ZY, Hsieh MY, Wang LY, Yu ML, Chang WY.

Liver Int. 2004 Dec;24(6):595-602.

PMID:
15566510
2.

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, Chang WY, Chang TT, Hsieh TY, Liu CJ, Chen DS.

J Viral Hepat. 2005 May;12(3):283-91.

PMID:
15850469
3.

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.

Mangia A, Ricci GL, Persico M, Minerva N, Carretta V, Bacca D, Cela M, Piattelli M, Annese M, Maio G, Conte D, Guadagnino V, Pazienza V, Festi D, Spirito F, Andriulli A.

J Viral Hepat. 2005 May;12(3):292-9.

PMID:
15850470
4.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
5.

Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT.

Jacobson IM, Ahmed F, Russo MW, Lebovics E, Dieterich DT, Esposito SP, Bach N, Klion F, Tobias H, Antignano L, Brown RS Jr, Gabbaizadeh D, Geders J, Levendoglu H.

Am J Gastroenterol. 2004 Sep;99(9):1700-5. Erratum in: Am J Gastroenterol. 2004 Oct;99(10):2075.

PMID:
15330905
6.

Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.

Tomimatsu M, Aizawa Y, Chuganji Y, Ishizuka H, Fujita Y, Aizawa R, Abe H, Matsuda T, Itou Y, Nakanishi H, Ushiyama H, Higuchi T, Fujimoto T, Endou H, Iga D, Ohta K, Kuroda H.

J Gastroenterol Hepatol. 2006 Jul;21(7):1177-83.

PMID:
16824072
7.

A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan.

Yu ML, Dai CY, Lin ZY, Lee LP, Hou NJ, Hsieh MY, Chen SC, Hsieh MY, Wang LY, Chang WY, Chuang WL.

Liver Int. 2006 Feb;26(1):73-81.

PMID:
16420512
9.

Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C.

August-Jörg BS, Borovicka J, Dufour JF, Gonvers JJ, Henz S, Hermann R, Meyenberger C, Weitz M, Renner EL; Swiss Association for the Study of the Liver..

Swiss Med Wkly. 2003 Aug 23;133(33-34):455-60.

10.

A randomized trial of a 4- vs 12-week daily interferon dose regimen combined with ribavirin in treatment of patients with chronic hepatitis C.

Sarin SK, Goyal A, Kumar S, Guptan RC, Hashmi AZ, Sakhuja P, Malhotra V.

Hepatobiliary Pancreat Dis Int. 2004 Feb;3(1):42-8.

11.

High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.

Tsubota A, Arase Y, Suzuki F, Suzuki Y, Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kumada H.

J Gastroenterol. 2004;39(2):155-61.

PMID:
15069622
12.

Treatment of chronic hepatitis C in southern Taiwan.

Chuang WL, Yu ML, Dai CY, Chang WY.

Intervirology. 2006;49(1-2):99-106. Review.

PMID:
16166797
13.

Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.

Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, Varghese R, Al-Nakib B.

Am J Gastroenterol. 2004 Sep;99(9):1733-7.

PMID:
15330911
14.

A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1.

Tassopoulos NC, Tsantoulas D, Raptopoulou M, Vassiliadis T, Kanatakis S, Paraskevas E, Vafiadis I, Avgerinos A, Tzathas C, Manolakopoulos S, Ketikoglou I, Aggelis P, Goritsas K, Giannoulis G, Hatzis G G, Thomopoulos K, Akriviadis E, Sypsa V, Hatzakis A.

J Viral Hepat. 2003 May;10(3):189-96.

PMID:
12753337
15.
16.
17.

Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.

Shiffman ML, Hofmann CM, Gabbay J, Luketic VA, Sterling RK, Sanyal AJ, Contos MJ, Ryan MJ, Yoshida C, Rustgi V.

Am J Gastroenterol. 2000 Oct;95(10):2928-35.

PMID:
11051370
18.

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.

Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC Jr, Esposito SP, Brown RS Jr, Bräu N, Klion FM, Tobias H, Bini EJ, Brodsky N, Cerulli MA, Aytaman A, Gardner PW, Geders JM, Spivack JE, Rahmin MG, Berman DH, Ehrlich J, Russo MW, Chait M, Rovner D, Edlin BR.

Am J Gastroenterol. 2005 Nov;100(11):2453-62.

PMID:
16279900
19.

Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled study.

Benetti G, Borzio M, Ramella G, Bellati G, Fargion S, Colombo A, Croce G, Iamoletti C, Balzola F, Rizzetto M; GEL (Gruppo Epatologico Lombardo)..

Intern Emerg Med. 2006;1(2):113-8.

PMID:
17111783
20.

Co-infection of SENV-D among chronic hepatitis C patients treated with combination therapy with high-dose interferon-alfa and ribavirin.

Dai CY, Chuang WL, Chang WY, Chen SC, Lee LP, Hsieh MY, Hou NJ, Lin ZY, Hsieh MY, Wang LY, Yu ML.

World J Gastroenterol. 2005 Jul 21;11(27):4241-5.

Items per page

Supplemental Content

Support Center